
Roche has announced that it is to terminate two Phase 3 studies investigating the efficacy of its anti-beta-amyloid molecule crenezumab …
A Phase II clinical trial for Genentech’s investigational Alzheimer’s drug failed to meet its primary endpoints – but the company …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

